September 2025 in “The health sciences AUS.” Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
November 2022 in “Journal of Investigative Dermatology” KX-826 is safe and effectively increases hair count in men with hair loss.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
9 citations
,
June 2017 in “Pharmacological Reports” ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.
October 2023 in “Dermatologie pro praxi” Alopecia areata causes hair loss and has various treatment options, but responses differ.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
Both treatments for localized alopecia areata are equally effective.
1 citations
,
January 2010 in “uO Research (University of Ottawa)” Atrazine and finasteride disrupt hormone signaling and affect frog development.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
October 2012 in “Semina. Ciências Agrárias” A Shi Tzu dog with high cortisol levels improved after increasing the dose of trilostane.
6 citations
,
December 2015 in “Journal of Dermatological Case Reports” Intradermal testing can better detect corticosteroid allergies than patch testing.
August 2025 in “Pediatric Dermatology” Individual choice in treating alopecia areata greatly impacts quality of life.
Low levels of tenuazonic acid can severely damage vital organs.
July 2024 in “International Journal of Pharmaceutical Sciences and Medicine” Nyctanthes arbor-tristis is effective for treating many health issues.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
5 citations
,
August 2021 in “Journal of Ethnobiology and Ethnomedicine” Smilax aristolochiifolia is declining in Puebla, Mexico, needing conservation efforts.
4 citations
,
January 2023 in “Journal of Clinical Investigation” Specific mutations in a receptor cause facial abnormalities and hair loss.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
43 citations
,
May 1999 in “Journal of Biological Chemistry” Agouti protein affects melanocortin receptors through competitive antagonism and receptor down-regulation.